HeartFlow

43 articles with HeartFlow

• Presented at SCCT - New Plaque Clinical Data Provides Additional Insights on Anatomy and Physiology in Clinical Decision Making for Patients

  7/21/2022

  HeartFlow, Inc., the leader in revolutionizing precision heart care, released two datasets utilizing its HeartFlow AI-based Plaque technology* (referred in below as “HeartFlow Plaque”).

• 

  BioSpace Movers & Shakers, March 4

  3/4/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• HeartFlow Announces Mutual Termination of Business Combination Agreement

  2/4/2022

  HeartFlow Holding, Inc. today announced that it and Longview Acquisition Corporation II (NYSE: LGV), a special purpose acquisition company sponsored by affiliates of Glenview Capital Management, LLC, have mutually agreed to terminate their previously announced business combination agreement, effective immediately, as a result of current unfavorable market conditions. 

• HeartFlow Appoints Timothy Barabe to its Board of Directors

  1/18/2022

  HeartFlow Holding, Inc., the leader in revolutionizing precision heart care, announced the appointment of Timothy Barabe to its Board of Directors.

• HeartFlow Appoints Dr. Wayne J. Riley to its Board of Directors

  11/15/2021

  HeartFlow, Inc., the leader in revolutionizing precision heart care, announced the appointment of Wayne J. Riley, MD, to its Board of Directors.

• HeartFlow Holding, Inc. to Participate in Upcoming Virtual Investor Conferences

  11/4/2021

  HeartFlow Holding, Inc ., the leader in revolutionizing precision heart care, today announced the company will be participating in two upcoming virtual investor conferences.

• HeartFlow Analysis is First AI-Enabled Technology to be Recognized by the American College of Cardiology and American Heart Association Guidelines as an Important Tool in Diagnosing and Treating Heart Disease

  10/28/2021

  HeartFlow, Inc. welcomed new clinical practice guidelines from the American College of Cardiology and American Heart Association that recognized the HeartFlow FFRct Analysis with Class of Recommendation 2a, identifying it as an important tool for diagnosing coronary artery disease and guiding decision-making regarding the use of revascularization procedures such as coronary stenting or bypass surgery.

• HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE TrialTrial to evaluate new technology that may help physicians prevent heart attacks in patients

  10/14/2021

  HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to AnaLyze PLAQUE using CCTA) trial to evaluate HeartFlow’s non-invasive plaque technology, an automated, deep learning-based method for identifying, characterizing and segmenting plaque in the coronary arteries.

• HeartFlow to Present at the Morgan Stanley Global Healthcare Conference

  9/1/2021

  HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference.

• 

  BioSpace Movers & Shakers, Aug. 6

  8/6/2021

  Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.
• 

  Medtech HeartFlow Joins SPAC Movement, Plans to List on NYSE

  7/16/2021

  Medtech company HeartFlow is heading to the New York Stock Exchange through a merger with special purpose acquisition company, Longview Acquisition Corp. II. 

• HeartFlow, the Leader in Precision Heart Care, Announces Merger with Longview Acquisition Corp. II to Become a Publicly Traded Company

  7/15/2021

  HeartFlow announced today that they have entered into a definitive business combination agreement that will support HeartFlow’s vision of revolutionizing precision heart care.

•  Late-Breaking Data Confirm the Accuracy of the HeartFlow Planner in Modeling Post-PCI Outcomes

  5/19/2021

  HeartFlow, Inc., a leader in revolutionizing precision heartcare, announced new data demonstrating the accuracy of the HeartFlow Planner in providing modeled post-percutaneous coronary intervention fractional flow reserve derived from computed tomography values, which are an important measure for understanding the effectiveness of a PCI procedure, such as a stent implantation.

• New 10-Year Data Demonstrate Superiority of the HeartFlow Analysis in Predicting Long-Term Outcomes in Patients With Coronary Artery Disease

  5/18/2021

  HeartFlow, Inc., a leader in revolutionizing precision heartcare, announced new data which indicate that the information provided by the HeartFlow FFRct Analysis was a superior predictor of 10-year outcomes compared to the severity of a coronary stenosis shown on a coronary computed tomography angiogram.

• HeartFlow Announces Completion of Patient Enrollment in the PRECISE Trial

  5/11/2021

  HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced the completion of patient enrollment in the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) randomized controlled trial. Physicians from more than 50 hospitals around the world successfully enrolled 2,100 patients.

• NICE Renews Support for Use of AI-powered HeartFlow Analysis in Heart Disease Diagnosis

  4/26/2021

  HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National Institute of Health and Care Excellence (NICE) has renewed its support for the use of its AI-powered HeartFlow® FFRct Analysis to fight coronary heart disease (CHD), one of the leading causes of death in the UK.

• NHS England and NHS Improvement Mandate Adoption of AI-powered HeartFlow Analysis to Fight Coronary Heart Disease

  1/26/2021

  Funding for the AI-powered coronary heart disease diagnostic technology also extended under NHS England’s Innovation and Technology Payment Programme

• New JAMA Network Open Publication Demonstrates the Coronary CT- HeartFlow Analysis Pathway Is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis

  12/14/2020

  HeartFlow, Inc., a leader in revolutionizing precision heartcare, announced that a new cost-effectiveness analysis found a diagnostic pathway which utilizes coronary computed tomography angiography with the HeartFlow FFRct Analysis to be “dominant” as compared to stress testing for assessing patients with coronary artery disease, the leading cause of death.

• HeartFlow Applauds Healthcare Stakeholders’ Push for Change in How Coronary Artery Disease is First Diagnosed

  10/29/2020

  Use of coronary CTA instead of stress tests alone results in increased early initiation of preventative therapy and 41% reduction in cardiac death and myocardial infarction

• HeartFlow Announces FDA Clearance for HeartFlow Planner

  9/12/2019

  HeartFlow, Inc. today announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non-invasive, real-time virtual modeling tool for coronary artery disease (CAD) intervention.